<DOC>
	<DOCNO>NCT00857363</DOCNO>
	<brief_summary>The protocol describe herein design provide clinical evidence substantial equivalence SmartPill GI Monitoring System ( SP ) Sitzmarks ( Konsyl Pharmaceuticals , Easton , MD ) radio-opaque marker ( ROM ) . The trial enroll symptomatic subject meet Rome III criterion ( 1 ) chronic functional constipation .</brief_summary>
	<brief_title>Colonic Transit Time Validation Study</brief_title>
	<detailed_description>The primary aim study assess equivalence SP ROM characterization device agreement use SP cutoff colonic whole gut transit ( 59hrs 73 hr respectively ) derive mention study . The cutoff derive 95th percentile healthy subject study . Demonstration agreement also serve validate SP cutoff . Device agreement evaluate compare percentage subject identify slow transit versus normal transit SmartPill percentage subject identify slow versus normal transit ROM study population . The colonic transit time result serve primary measure slow versus normal transit SmartPill . For ROM test employ Metcalf protocol provide measure whole gut transit compare SmartPill result . Additionally , characterize gastric empty small bowel transit time SmartPill population . The SmartPill test administer simultaneously ROM . A modify Metcalf procedure employ characterization slow transit ROM . The SmartPill GI Monitoring System offer alternative non-invasive method characterize disorder stomach . The system consist ingestible capsule house sensor pH , temperature , pressure , receiver receive store signal capsule , software display data personal computer . The capsule sample regular interval transmits sense pH , pressure , temperature data portable receiver worn subject . After test completion , record data download personal computer subsequent evaluation . This trial subject 18 year age 80 year age .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>1 . Males female age 1880 year age symptoms chronic functional constipation least one year . 2 . Self report bowel movement frequency &lt; 2 bowel movements/week least 3 last 6 month . 3 . Presenting least one follow symptom define Rome III criterion Feeling incomplete evacuation &gt; 25 % bowel movement Digital maneuver &gt; 25 % bowel movement Hard stool &gt; 25 % bowel movement Feeling blockage &gt; 25 % bowel movement Straining &gt; 25 % bowel movement 4 . Constipation , abdominal pain , predominant symptom . 5 . Ability stop laxative , prokinetic agent , narcotic analgesic agent 3 day prior SP ROM ingestion visit study period . 6 . Ability stop proton pump inhibitor seven day Histamine2 blocker three day prior day SmartPill ingestion . 7 . No evidence metabolic disease ( hypothyroidism , uncontrolled diabetes , electrolyte imbalance ) . 8 . A normal colonoscopy barium enema within 5 year individual 50 year age . 1 . Participation previous SmartPill Whole gut transit Study title `` Assessment Whole Gut Transit Time Using SmartPill Capsule : A Multicenter Study '' Protocol Number 122205 2 . Previous history bezoars . 3 . Prior GI surgery except cholecystectomy , appendectomy , Nissen fundoplication 4 . Any abdominal surgery within past 3 month 5 . Known history inflammatory bowel disease 6 . History diverticulitis , diverticular stricture , intestinal stricture 7 . Tobacco use within eight hour prior capsule ingestion initial 8 hour record Day 0 Ingestion visit . 8 . Alcohol use within eight hour prior capsule ingestion throughout entire monitoring period ( 5 day ) . 9 . BMI &gt; 40 kg/m2 10 . Allergies component SmartBar ( Appendix IX ) . 11 . Females childbearing age practice birth control and/or pregnant lactating . ( A urine pregnancy test perform female subject prior capsule ingestion ) . Acceptable form birth control include oral contraceptive , double barrier method , IUD cover must practice time enrollment time release study . 12 . Cardiovascular , endocrine , renal , chronic disease likely affect motility . 13 . Use medical device pacemaker , infusion pump , insulin pump . 14 . Any contraindication use Fleets Enema . 15 . Uncontrolled diabetes hemoglobin A1C great 10 % . 16 . Severe dysphagia food pill</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>capsule</keyword>
	<keyword>constipation</keyword>
	<keyword>whole gut transit</keyword>
	<keyword>colonic transit</keyword>
	<keyword>gastric empty</keyword>
	<keyword>small bowel transit</keyword>
</DOC>